Combination of Topiramate and Empagliflozin is Considered a Good Option for the Treatment of Obesity

Mahmoud Younis
Additional contact information
Mahmoud Younis: University of Ain shams, Egypt

JOJ Internal Medicine, 2019, vol. 1, issue 2, 38-46

Abstract: The incidence of obesity has raised very much in the latest decades in which more than 30% of peoples are considered obese. It is evidenced that genetics has a great impact on obesity occurrence; all in all, the risk of getting obesity in the future is linked to many factors like sedentary lifestyle, type of diet. Aside from decreasing blood glucose, empagliflozin can lead to a reduction of weight due to the loss of calories by excretion of glucose. Research papers also discuss the weight reducing effect of topiramate and demonstrated that this effect is dependent on the dose of the drug and duration of treatment.

Keywords: journal of orthopaedics; orthopaedics journals impact factor; orthopaedics articles impact factor; scholarly publishing orthopedics journals; juniper publishers opena ccess orthopedics journal; Rheumatology; rheumatology journals impact factor 2018; rheumatology journals impact factor; rheumatology open access journals; juniper publishers review (search for similar items in EconPapers)
Date: 2019
References: Add references at CitEc
Citations:

Downloads: (external link)
https://juniperpublishers.com/jojim/pdf/JOJIM.MS.ID.555558.pdf (application/pdf)
https://juniperpublishers.com/jojim/JOJIM.MS.ID.555558.php (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:adp:jjojim:v:1:y:2019:i:2:p:38-46

DOI: 10.19080/JOJIM.2019.01.555558

Access Statistics for this article

JOJ Internal Medicine is currently edited by Sophia Mathis

More articles in JOJ Internal Medicine from Juniper Publishers Inc.
Bibliographic data for series maintained by Robert Thomas ().